CAR T Cells Motoring to Market — by Next Year? – Medscape
Medscape |
CAR T Cells Motoring to Market — by Next Year?
Medscape Novartis' product is CTL019, an anti-CD19 CAR T-cell therapy. The product, which is currently named tisagenlecleucel-T, was developed for use in the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL) in pediatric patients. Results … Can CAR–T cancer treatments be fine-tuned to avoid toxic side effects? CD22-Targeted CAR T-Cell Therapy Active for Relapsed/Refractory ALL Anti-CD22 CAR T-Cell Salvage Therapy Succeeds in Pediatric ALL |
